AZD8055

Catalog No.S1555

Molecular Weight(MW): 465.54

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Cited by 40 Publications

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Res, 2018, 78(12):3176-3189

PubMed: 29661831 ( click the link to review the publication )

Cancer Cell, 2015, 27(1):97-108

PubMed: 25544637 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

J Clin Invest, 2014, 10.1172/JCI73935

PubMed: 25415435 ( click the link to review the publication )

Genome Biol, 2016, 17(1):149

PubMed: 27380875 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Autophagy, 2012, 9(1):74-92

PubMed: 23196898 ( click the link to review the publication )

Cancer Res, 2015, 75(20):4398-406

PubMed: 26359452 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2014, 74(14):3947-58

PubMed: 24986516 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )
Cell Rep, 2015, 11(3):446-59

PubMed: 25865887 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28880

PubMed: 24706460 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 20(9):1382-95

PubMed: 24063548 ( click the link to review the publication )

Am J Transplant, 2013, 13(8):2035-43

PubMed: 23841834 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Cell Commun Signal, 2017, 10.1186/s12964-017-0164-3

PubMed: 28143584 ( click the link to review the publication )

Mol Oncol, 2013, 33:404-18

PubMed: 24444656 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Clin Sci, 2015, 128(8):517-26

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Exp Neurol, 2012, 233(2):799-806

PubMed: 22177999 ( click the link to review the publication )
Biochem Pharmacol, 2012, 83(9):1183-94

PubMed: 22305748 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074/jbc.C114.627778

PubMed: 25833948 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35287-96

PubMed: 24133218 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-837

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

J Chromatogr A, 2015, 1388:267-73

PubMed: ( click the link to review the publication )

Proteomics, 2015, 10.1002/pmic.201400586

PubMed: 25764225 ( click the link to review the publication )

Mol Biol Cell, 2013, 24(23):3736-45

PubMed: 24088573 ( click the link to review the publication )

Mol Reprod Dev, 2014, 81(7):655-65

PubMed: 24753052 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0154564

PubMed: 27128484 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )
Biochem Biophys Res Commun, 2013, 440(4):701-6

PubMed: 24103749 ( click the link to review the publication )

Oncol Lett, 2013, 5(2):717-721

PubMed: 23420667 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6015-27

PubMed: 24970798 ( click the link to review the publication )

8 Customer Reviews

PC3-LN4 cells were treated with GSK690693 (5 uM) alone, or in combination with PP242 (2 uM) or AZD8055 (1 uM) for 24 h, and immunoblotting performed.

Cancer Res 2013 73(11), 3402-11. AZD8055 purchased from Selleck.

mTOR kinase inhibitor AZD8055 activates PI3K accompanied with induction of expression of EGFR, HER2, HER3 and IRS1. Serum-deprived CHO-EGFP-AKT cells were incubated with 50 nM AZD8055 for 24 hr. The EGFP signal was detected using confocal microscopy. The white arrows indicate EGFP-AKT located on cellular membrane.

Int J Cancer 2014 135(10), 2462-74. AZD8055 purchased from Selleck.
HUVEC were treated with either RAD001 or AZD8055 before PA treatment. p53, GPX1, p53 acetylation, and subcellular PTEN were analyzed with corresponding antibodies. The blot is a representative of the results of three experiments. Values (mean盨D) are expressed as fold over untreated control. *p<0.05 versus their corresponding control groups in the one-way ANOVA.

Antioxid Redox Signal 2014 20(9), 1382-95. AZD8055 purchased from Selleck.

CSCs^+24/44/ESA at 5,000 cells per well with stem cell culture media in triplicate in an ultra-low adhesion plate were treated with 5 umol/L BMS-777607, 1 umol/L AZD8055 alone, or in their different combinations. Cells were cultured for 72 hours. Cell viability was determined by the MTS assay. Percentages of polyploid cells were determined by counting 300 cells from two different regions. Results shown here were from one of two experiments with similar results.

Mol Cancer Ther 2014 13(1), 37-48. AZD8055 purchased from Selleck.
mTOR, P70S6K1, 4E-BP1 and PCNA activation in the basilar artery of SAH. Top, Western blotting bands of antibodies, bottom, density of the protein band from each group. A, mTOR activation in the basilar artery demonstrated an elevated expression of mTOR on day 7 following SAH in SAH and SAH+DMSO animals. The mTOR inhibitors, Rapamycin and AZD8055 reduced the enhanced expression of mTOR (pb0.05, ANOVA). B. P70S6K1 activation. C. 4E-BP1 activation. D. PCNA activation. Rapamycin and AZD8055 significantly decreased the expression of P70S6K1, 4E-BP1 and PCNA compared with the SAH and SAH+DMSO (pb0.05, respectively; ANOVA). There was no significant difference between the two inhibitors in mTOR, P70S6K1, 4E-BP1 and PCNA expression.

Exp Neurol 2012 233, 799-806. AZD8055 purchased from Selleck.

Induction of TCTP expression through 5-FU or oxaliplatin is inhibited by mTOR kinase inhibitors. HCT116 cells were treated for 48 h with 5-FU or oxaliplatin at the indicated concentrations. Where indicated, AZD 8055 (100 nM) or PP242 (1 μM) were added. TCTP levels were assessed by western blotting; signals were quantified and normalised against α-tubulin as a loading control. As a readout of mTOR activity, phosphorylation of the ribosomal protein S6 at Ser 240/244 was assessed using a phospho-specific antibody. a. Representative western blots demonstrating the alteration of the levels of TCTP protein and of phospho-ribosomal protein S6, respectively, in relation to the drug concentration.

Cell Commun Signal, 2017, 15(1):9. AZD8055 purchased from Selleck.
(A) HCT116 or MDA-MB-468 cells were treated with 500 nM AZD8055 for the indicated times. Cell lysates were immunoblotted with the indicated antibodies. (B) HCT116 or MDA-MB-468 cells were treated with 50 nM rapamycin. 500 nM AZD8055, 1 uM MK2206 or dimethyl sulfoxide (DMSO) as control for 12 h. Cell lysates were immunoblotted with the indicated antibodies.

Oncotarget 2014 5(15), 6015-27. AZD8055 purchased from Selleck.

After starved in serum-free medium for 24h , A549 cells incubated with the indicated concentrations of AZD8055 for 3h , followed by 20-minute stimolation of 100ng/ml EGF

Dr. Zhang of Tianjin Medical University. AZD8055 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features

First drug to inhibit both types of mTOR protein.

Targets

mTOR (truncated) ^[1] (MDA-MB-468 cells)	mTOR (full length) ^[1] (MDA-MB-468 cells)
0.13 nM	0.8 nM

In vitro

AZD8055 shows low activity (∼1,000-fold) against all PI3K isoforms (α, β, γ, δ) and other members of the PI3K-like kinase family (ATM and DNA-PK). AZD8055 inhibits the phosphorylation of mTORC1 (p70S6K and 4E-BP1) as well as phosphorylation of the mTORC2 (Akt) and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 can be fully inhibited by AZD8055, resulting in significant inhibition of cap-dependent translation. AZD8055 potently inhibits proliferation in U87MG, A549 and H838 cells with IC50 of 53, 50 and 20 nM, respectively. AZD8055 also induces autophagy and increased LC3-II levels in H838 and A549 cells. ^[1] AZD8055 decreases AML blast cell proliferation and cell cycle progression, reduces the clonogenic growth of leukemic progenitors and induces caspase-dependent apoptosis in leukemic cells but not in normal immature CD34+ cells. ^[2] AZD8055 indicates inhibitory against the pediatric preclinical testing program (PPTP) cell lines with IC50 of 24.7 nM and induces significant differences in EFS distribution. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
LU-139	NHv0RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rZbWlEPTB;MD6wNlM{OSEQvF2=	NGn6d3lUSU6JRWK=
NCI-H720	NF62WnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LxbWlEPTB;MD6wNlk{QCEQvF2=	NHntUo1USU6JRWK=
KARPAS-45	M{HqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTBwMEOzO\|Eh\|ryP	NIXrTJRUSU6JRWK=
EW-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTBwMESwOVYh\|ryP	NH;EeFVUSU6JRWK=
SBC-1	NIKyVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnOWZFKSzVyPUCuNFQ2QDFizszN	MnPxV2FPT0WU
NCI-H209	NUT4RYozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPkTWM2OD1yLkC1OFU{KM7:TR?=	NUTqUFNGW0GQR1XS
EoL-1-cell	NFn1SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTBwME[1Olkh\|ryP	NFnteIRUSU6JRWK=
H9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2r2TmlEPTB;MD6wOlY6OiEQvF2=	MkH4V2FPT0WU
AN3-CA	M{Hzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;hd2lEPTB;MD6wO\|k2OSEQvF2=	NVPOOoxlW0GQR1XS
HH	NIXmeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwMEiwNFkh\|ryP	MXTTRW5ITVJ?
KU812	NWOxd49VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3NTVVKSzVyPUCuNFgxPDNizszN	MkLWV2FPT0WU
DU-4475	NF7BTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEno[IhKSzVyPUCuNFgxPDdizszN	NXXnZngzW0GQR1XS
CTV-1	M1rE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfrNWVZUUN3ME2wMlA5PjRzIN88US=>	NWnZT3VHW0GQR1XS
BV-173	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXhTWM2OD1yLkC5NFYyKM7:TR?=	MXHTRW5ITVJ?
ES5	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrI[nZVUUN3ME2wMlA6OzVizszN	MUHTRW5ITVJ?
G-402	NEnnZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1z4[WlEPTB;MD6wPVk5KM7:TR?=	MV\TRW5ITVJ?
MV-4-11	NXXqSpRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDFTWM2OD1yLkGwN\|Q4KM7:TR?=	MXzTRW5ITVJ?
NB69	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\2VZVrUUN3ME2wMlE{PSEQvF2=	M4TEV3NCVkeHUh?=
EGI-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rCS2lEPTB;MD6xN\|U{OSEQvF2=	MmP5V2FPT0WU
EW-18	NYLhZmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jwZ2lEPTB;MD6xOFA4OyEQvF2=	NYLsNpJUW0GQR1XS
ME-180	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvLdmtKSzVyPUCuNVQ3QDFizszN	MXLTRW5ITVJ?
D-283MED	NHS3WJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTBwMUS3NlMh\|ryP	MnfVV2FPT0WU
NB14	NV7aWWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTBwMU[0OFch\|ryP	NVu5PGp4W0GQR1XS
Ramos-2G6-4C10	M1;NeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTBwMU[5PFMh\|ryP	M{\IbHNCVkeHUh?=
NBsusSR	MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTBwMUewNVkh\|ryP	NILqU5lUSU6JRWK=
LAMA-84	M1;LfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfpTWM2OD1yLkG4NFMzKM7:TR?=	Mnv6V2FPT0WU
NCI-H1581	NGfjTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\vOmlEPTB;MD6xPFk3PiEQvF2=	NEX5NW5USU6JRWK=
A204	NUDxOVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT4OoxmUUN3ME2wMlE5QTdizszN	MXXTRW5ITVJ?
A549	M4HBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTBwMUm1OUDPxE1?	NXK3UXpDW0GQR1XS
CAL-51	MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTBwMUm2OVEh\|ryP	NHnGU5RUSU6JRWK=
NKM-1	NHruWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzZW\|RKSzVyPUCuNlAxOjlizszN	MX3TRW5ITVJ?
LoVo	NUmzXo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LJbWlEPTB;MD6yNFIxOiEQvF2=	MX7TRW5ITVJ?
HAL-01	NVf2WHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofMTWM2OD1yLkKwNlk4KM7:TR?=	M1vKTHNCVkeHUh?=
HCC2218	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\ITWM2OD1yLkKwOlg5KM7:TR?=	MXPTRW5ITVJ?
BEN	NUfXOJo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\ITo1KSzVyPUCuNlEzQTNizszN	NF\MSZhUSU6JRWK=
LC-2-ad	NFPFUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrhT5R7UUN3ME2wMlIzODh2IN88US=>	MmrrV2FPT0WU
LXF-289	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TuUWlEPTB;MD6yOVA1OSEQvF2=	M2L0V3NCVkeHUh?=
HGC-27	NYHofXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\lTWM2OD1yLkK2OFE1KM7:TR?=	NXjwdIc6W0GQR1XS
LK-2	NGHu[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;Ub2lEPTB;MD6yOlgzPCEQvF2=	NEL0[3BUSU6JRWK=
CTB-1	NIHUV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDz[mh7UUN3ME2wMlI4OjF3IN88US=>	Ml;zV2FPT0WU
697	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTBwMkezOlch\|ryP	NHjlVYRUSU6JRWK=
ES7	NVPsWVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\ITWM2OD1yLkK3N\|g{KM7:TR?=	MoDqV2FPT0WU
MG-63	MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTVTWM2OD1yLkK3OFA4KM7:TR?=	MnP6V2FPT0WU
T47D	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\iTWM2OD1yLkK3OFc2KM7:TR?=	MXTTRW5ITVJ?
RPMI-8226	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLBTWM2OD1yLkK4OVg6KM7:TR?=	MV;TRW5ITVJ?
NCI-H292	M3n0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXe3W5E{UUN3ME2wMlI6OTZ2IN88US=>	NXW5fnpPW0GQR1XS
HT	NVXWd3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjrTWM2OD1yLkK5N\|gh\|ryP	MUTTRW5ITVJ?
A3-KAW	NE\ZXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTBwMkm3OEDPxE1?	NGX5V4lUSU6JRWK=
LB2241-RCC	NFvvVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwM{CxPVgh\|ryP	MkDZV2FPT0WU
BB65-RCC	M1TKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfiTWM2OD1yLkOwPFA2KM7:TR?=	M2jRVnNCVkeHUh?=
G-401	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwM{C5PFYh\|ryP	NGe5NYVUSU6JRWK=
TYK-nu	NVrifoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHiTWM2OD1yLkOxPFY1KM7:TR?=	MV\TRW5ITVJ?
NCI-SNU-1	M2fqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTBwM{KzN\|Eh\|ryP	M{fmbnNCVkeHUh?=
CHL-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTBwM{K3NFMh\|ryP	NVftTYxQW0GQR1XS
P30-OHK	M4jMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zibmlEPTB;MD6zNlcxPSEQvF2=	NUHyNVZCW0GQR1XS
PA-1	NVm0cVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwM{O2NVkh\|ryP	MWLTRW5ITVJ?
LB1047-RCC	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M325b2lEPTB;MD6zOFA1PyEQvF2=	M4Pae3NCVkeHUh?=
EM-2	NXLyTHBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTBwM{SxPFgh\|ryP	MkDtV2FPT0WU
VA-ES-BJ	NXLDSnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzMelRSUUN3ME2wMlM1OjZ6IN88US=>	MkjDV2FPT0WU
NCI-H520	NFS0VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTBwM{S4N\|Qh\|ryP	NGnneppUSU6JRWK=
ECC10	M1XDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfETWM2OD1yLkO1NFM2KM7:TR?=	MVXTRW5ITVJ?
LNCaP-Clone-FGC	M3PpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX[0eXNHUUN3ME2wMlM2OzF2IN88US=>	M2HYenNCVkeHUh?=
ES8	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTBwM{[1OVMh\|ryP	MUPTRW5ITVJ?
HuO-3N1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLLTWM2OD1yLkO4N\|c6KM7:TR?=	NGLtcGtUSU6JRWK=
L-363	NYGxOYI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nse2lEPTB;MD6zPVAzPiEQvF2=	M1TpeXNCVkeHUh?=
SK-LU-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfHZ4Z5UUN3ME2wMlM6OjB6IN88US=>	NVLiUoNQW0GQR1XS
MCF7	NHP4XpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwNEC1N{DPxE1?	NEK1[WVUSU6JRWK=
HuO9	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHqTWM2OD1yLkSwOlY4KM7:TR?=	MV\TRW5ITVJ?
BHT-101	NVXEXpBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjFeGE1UUN3ME2wMlQxPzh5IN88US=>	NXLwblBmW0GQR1XS
MZ2-MEL	NXu4OHA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnv1TWM2OD1yLkSwPFgzKM7:TR?=	Mn\4V2FPT0WU
NOS-1	M4DaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTBwNEGwO\|Qh\|ryP	Mki5V2FPT0WU
NEC8	NXSyfIM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13hXGlEPTB;MD60NVY6PSEQvF2=	M2HHOXNCVkeHUh?=
COR-L88	M3;ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYT3Smd1UUN3ME2wMlQzOjZ5IN88US=>	NIX3[YZUSU6JRWK=
MFM-223	M1;SOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrIUm5pUUN3ME2wMlQzPjF5IN88US=>	NF7yb5lUSU6JRWK=
HSC-3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTBwNEK5NFgh\|ryP	M3OwcHNCVkeHUh?=
OVCAR-5	NInGVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTBwNEK5N\|Mh\|ryP	NFK5NmtUSU6JRWK=
MFE-280	NEmwe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HCfGlEPTB;MD60N\|A{OiEQvF2=	M3O0OXNCVkeHUh?=
KP-N-YS	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M123N2lEPTB;MD60N\|A4KM7:TR?=	MlfVV2FPT0WU
EPLC-272H	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37JV2lEPTB;MD60N\|A4PyEQvF2=	M1Oy[nNCVkeHUh?=
KE-37	M1\nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnYOodKSzVyPUCuOFMzPDdizszN	MVvTRW5ITVJ?
HuH-7	NHfVfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDxTWM2OD1yLkSzN\|czKM7:TR?=	NHe3N3hUSU6JRWK=
CHP-212	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfCdJJKSzVyPUCuOFM3QTdizszN	NG[zRm9USU6JRWK=
SK-MES-1	M37BOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXqfVhRUUN3ME2wMlQ{QDR6IN88US=>	MmDJV2FPT0WU
SJSA-1	NIO0[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vZfGlEPTB;MD60OFU2PCEQvF2=	MWnTRW5ITVJ?
QIMR-WIL	NELzU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVOzOFlGUUN3ME2wMlQ2OTVizszN	NXzUXYtwW0GQR1XS
ES4	MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\5TWM2OD1yLkS1N\|M3KM7:TR?=	MXXTRW5ITVJ?
TI-73	MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrQZZFKSzVyPUCuOFU3QDZizszN	M1TpVnNCVkeHUh?=
COLO-684	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwNEW3NlYh\|ryP	NVrNTVRYW0GQR1XS
GCIY	NHjyTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTBwNEW3OVQh\|ryP	M1vrOnNCVkeHUh?=
JVM-3	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDm[VNKSzVyPUCuOFYzQTJizszN	MofYV2FPT0WU
MPP-89	M{T2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jNVGlEPTB;MD60Olk1PyEQvF2=	NFfKU\|dUSU6JRWK=
M14	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TwfmlEPTB;MD60O\|E4KM7:TR?=	M3S4WnNCVkeHUh?=
SW962	NFHRNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWK3NYhoUUN3ME2wMlQ4OTlizszN	M4DqSXNCVkeHUh?=
VM-CUB-1	MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XicWlEPTB;MD60O\|I5PiEQvF2=	MlThV2FPT0WU
A101D	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfBTWM2OD1yLkS4PVY5KM7:TR?=	MV\TRW5ITVJ?
DB	MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjtTWM2OD1yLkWwNFIyKM7:TR?=	MXHTRW5ITVJ?
KNS-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWmwfWJiUUN3ME2wMlUxPTZ6IN88US=>	NETINHlUSU6JRWK=
NCI-H460	M{DRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rtcGlEPTB;MD61NFU6PyEQvF2=	NF[2TodUSU6JRWK=
MDA-MB-361	NWL0dFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvX[JdKSzVyPUCuOVA5PyEQvF2=	MXLTRW5ITVJ?
DOK	NWnmO2tYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3P6bmlEPTB;MD61NVM{OyEQvF2=	NYLLZmxJW0GQR1XS
CAL-39	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUD5OGxvUUN3ME2wMlUzOjZ6IN88US=>	MnP5V2FPT0WU
HT-1080	Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PvWGlEPTB;MD61NlU1OyEQvF2=	M3P2UXNCVkeHUh?=
GR-ST	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTBwNUOwNVUh\|ryP	NGLoZ5pUSU6JRWK=
J-RT3-T3-5	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwNUOxPVUh\|ryP	Ml20V2FPT0WU
NCI-H1793	NXvHflFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTBwNUO0OFch\|ryP	NFTDOZdUSU6JRWK=
NCI-H1355	M2SwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH3enRKSzVyPUCuOVM5PzhizszN	MlfoV2FPT0WU
YH-13	NYH6RYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TIdmlEPTB;MD61OFk{QCEQvF2=	NX7iPI1WW0GQR1XS
LOXIMVI	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTBwNUWxNlMh\|ryP	NITjXFdUSU6JRWK=
ES1	Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXG[lJKSzVyPUCuOVU2OThizszN	NVPxSVhCW0GQR1XS
GAMG	NWHXT5lKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\mWmlEPTB;MD61OVY2QCEQvF2=	NHzXW\|FUSU6JRWK=
SK-MEL-28	NXO1bYtGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jwN2lEPTB;MD61OVkyKM7:TR?=	MWXTRW5ITVJ?
KG-1	NGracppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDWbXdDUUN3ME2wMlU3QDh2IN88US=>	Mmj5V2FPT0WU
HOS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTJWmRzUUN3ME2wMlU4OTl{IN88US=>	MorTV2FPT0WU
PANC-08-13	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnniTWM2OD1yLkW3N\|g6KM7:TR?=	MnvWV2FPT0WU
SW780	M1PiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLqUHJKSzVyPUCuOVc2QTVizszN	MULTRW5ITVJ?
MDA-MB-175-VII	NXrybZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfSdHBKSzVyPUCuOVc4PDFizszN	NUPDS45UW0GQR1XS
MSTO-211H	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFO2VVBKSzVyPUCuOVc4PTFizszN	NFj2fVJUSU6JRWK=
ML-2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LIVmlEPTB;MD61PFQ4QCEQvF2=	MVjTRW5ITVJ?
SCC-4	NEHTVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwNUi1OFEh\|ryP	MV;TRW5ITVJ?
NCI-H1048	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTTPHhKSzVyPUCuOVg3PDVizszN	NX3lR\|FRW0GQR1XS
NCI-H28	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkGyTWM2OD1yLkW4Olc2KM7:TR?=	NWn2PG55W0GQR1XS
BCPAP	NWKyRY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlK2TWM2OD1yLkW4O\|kyKM7:TR?=	MnvkV2FPT0WU
PC-14	NFnyPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XpOmlEPTB;MD61PFk4KM7:TR?=	MX;TRW5ITVJ?
OAW-42	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4[zN2lEPTB;MD61PVE3OiEQvF2=	MX7TRW5ITVJ?
IA-LM	NV;SXpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnr6TWM2OD1yLkW5OlA6KM7:TR?=	MV;TRW5ITVJ?
Hs-578-T	NV:5PJdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTFc4FKSzVyPUCuOVk5PTFizszN	M{nacHNCVkeHUh?=
H4	NWD6VlFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTBwNkCwPVQh\|ryP	MV\TRW5ITVJ?
HL-60	M2DvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWL6Ong2UUN3ME2wMlYxOzVzIN88US=>	NXz3VHZZW0GQR1XS
NCI-H1437	M3eyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofZTWM2OD1yLk[wOlE6KM7:TR?=	NELM[2RUSU6JRWK=
KGN	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXOTWM2OD1yLk[xNFQ6KM7:TR?=	NFHsPVlUSU6JRWK=
NCI-H2452	NF74VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\jTWM2OD1yLk[xPVE4KM7:TR?=	NGT1eXRUSU6JRWK=
BFTC-905	NGn3XXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTBwNkKxNlYh\|ryP	MWHTRW5ITVJ?
CAMA-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDpTHVKSzVyPUCuOlIyPTJizszN	NEH2dmxUSU6JRWK=
SK-NEP-1	M4naUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PZdmlEPTB;MD62NlUxOiEQvF2=	NFrVbVJUSU6JRWK=
NCI-H522	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTyTWM2OD1yLk[yPVkzKM7:TR?=	NV3JeVc4W0GQR1XS
SW1710	M2XzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnxW5hKSzVyPUCuOlMyPjdizszN	NW\G[3FtW0GQR1XS
RVH-421	NHfuTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPYdocyUUN3ME2wMlY{PjN7IN88US=>	Mn20V2FPT0WU
SK-MEL-2	M{PvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXzTFNXUUN3ME2wMlY1OTV\|IN88US=>	Mn7TV2FPT0WU
KYSE-150	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPRV3o1UUN3ME2wMlY3OTh4IN88US=>	MXPTRW5ITVJ?
MOLT-13	NEm0OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;hTWM2OD1yLk[2OVM4KM7:TR?=	M{fvRnNCVkeHUh?=
SK-OV-3	NXrkcGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXlN3B2UUN3ME2wMlY4OTh5IN88US=>	Mn7aV2FPT0WU
IGROV-1	NX2z[WlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PLOmlEPTB;MD62O\|Q2KM7:TR?=	MUnTRW5ITVJ?
MOLT-4	M13CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXYTWM2OD1yLk[3Olg6KM7:TR?=	Mmf5V2FPT0WU
MEL-HO	NIruO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPnO3FTUUN3ME2wMlY4PzV{IN88US=>	Moq0V2FPT0WU
MDA-MB-157	NXXPZ\|M6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;HTWM2OD1yLk[3PFEh\|ryP	MkjqV2FPT0WU
MN-60	M1Xo[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPkTWM2OD1yLk[3PFQ3KM7:TR?=	NILQcYJUSU6JRWK=
EFO-27	Mm\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj4cm9KSzVyPUCuOlc6PzlizszN	NGrMbmpUSU6JRWK=
HO-1-N-1	M2K1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTBwNkiwOlQh\|ryP	NFjOOVFUSU6JRWK=
TE-5	NFjSZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkiwTWM2OD1yLk[4OFA2KM7:TR?=	MkfXV2FPT0WU
EW-22	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWT5cYFTUUN3ME2wMlY5PDR2IN88US=>	NFPNb\|dUSU6JRWK=
SW982	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XqUGlEPTB;MD62PFUxOSEQvF2=	MlO0V2FPT0WU
SF295	MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{O2RmlEPTB;MD62PFUxPyEQvF2=	MYHTRW5ITVJ?
WM-115	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnmZWs1UUN3ME2wMlY5QTJ2IN88US=>	NWPwVmllW0GQR1XS
COLO-800	NUXpO5NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTBwNkm4NVMh\|ryP	NEnQb\|ZUSU6JRWK=
NTERA-S-cl-D1	NYTOT496T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\DOWlEPTB;MD63NFA3OyEQvF2=	MUDTRW5ITVJ?
NCI-H1648	M13TVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HwOWlEPTB;MD63NFE4OyEQvF2=	MkXLV2FPT0WU
NB5	M2roW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTBwN{CzNVkh\|ryP	NULFWm03W0GQR1XS
ATN-1	NXzUZpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXiTWM2OD1yLkewOVkh\|ryP	Mn;SV2FPT0WU
NUGC-3	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3j4RmlEPTB;MD63NFY6OSEQvF2=	MmXTV2FPT0WU
22RV1	M2rDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwN{C3NVch\|ryP	MUDTRW5ITVJ?
8305C	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1:2TmlEPTB;MD63NFc2PSEQvF2=	M3fmNHNCVkeHUh?=
EFM-19	NHvudGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUm4TpJvUUN3ME2wMlcxQDR5IN88US=>	M1zQW3NCVkeHUh?=
PC-3	NUS5S4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PD[WlEPTB;MD63NlI{KM7:TR?=	MmLDV2FPT0WU
C32	NFvjUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPMNm9KSzVyPUCuO\|I1QDRizszN	MkG0V2FPT0WU
MC-IXC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3vUWZKSzVyPUCuO\|I4OThizszN	NIL4Z\|VUSU6JRWK=
OMC-1	NGrZTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjKU4VmUUN3ME2wMlczPzN6IN88US=>	MUjTRW5ITVJ?
HTC-C3	M4e3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Syd2lEPTB;MD63N\|E4OiEQvF2=	M1TWUnNCVkeHUh?=
RPMI-7951	NUi4PWd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTBwN{O1N\|Mh\|ryP	NXO1N2VJW0GQR1XS
AsPC-1	NYXWb5hFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELNbWZKSzVyPUCuO\|M4QTVizszN	NUDq[ndxW0GQR1XS
CAKI-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvnTWM2OD1yLke0OlI6KM7:TR?=	M{DubHNCVkeHUh?=
MHH-PREB-1	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTBwN{S3N\|Yh\|ryP	M1TlPHNCVkeHUh?=
HLE	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLyTWM2OD1yLke0PFQ1KM7:TR?=	MmS5V2FPT0WU
A375	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3:2NmlEPTB;MD63OVE6OyEQvF2=	NF2zSY5USU6JRWK=
RS4-11	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwN{W5OFMh\|ryP	NHfXS2dUSU6JRWK=
U-2-OS	M4L3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL6RoRYUUN3ME2wMlc2QTdizszN	NHjkXZJUSU6JRWK=
NCI-H747	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTBwN{W5PVEh\|ryP	MULTRW5ITVJ?
NCI-H1623	NH\1e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTBwN{[yOlEh\|ryP	NUTmeIlIW0GQR1XS
DMS-273	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwN{[5NlIh\|ryP	MWXTRW5ITVJ?
PSN1	NXfBeZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;QbWFKSzVyPUCuO\|cxPTdizszN	M1LFNXNCVkeHUh?=
LU-99A	M3rNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn3dWxKSzVyPUCuO\|c3PDlizszN	MlrCV2FPT0WU
CAL-12T	NYTVOIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\FTpBKSzVyPUCuO\|gxOjlizszN	MlX4V2FPT0WU
KYSE-140	NELEe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nKRWlEPTB;MD63PFE3QCEQvF2=	MmC0V2FPT0WU
VMRC-RCZ	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXLeXQ5UUN3ME2wMlc5PDh{IN88US=>	MWjTRW5ITVJ?
Ca9-22	M3SzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3yyTWlEPTB;MD63PFc{PiEQvF2=	NXzLeZQxW0GQR1XS
NCI-H1563	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\0UWlEPTB;MD63PFkzPiEQvF2=	NF\zeYRUSU6JRWK=
NCI-H650	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXmUGxLUUN3ME2wMlc6OTR2IN88US=>	Mm\FV2FPT0WU
DOHH-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3HNXVYUUN3ME2wMlc6OzNizszN	MmjxV2FPT0WU
OE33	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\5ZndKSzVyPUCuO\|k6OTRizszN	M3f1PHNCVkeHUh?=
CAL-62	NWnzfpZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vxZ2lEPTB;MD63PVkzPCEQvF2=	Mn\xV2FPT0WU
NCI-H1770	NG\2VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmewTWM2OD1yLkiwNlEh\|ryP	NV;GTZZCW0GQR1XS
SN12C	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fLRmlEPTB;MD64NFY3QCEQvF2=	MYXTRW5ITVJ?
HPAF-II	M3nVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXznRoViUUN3ME2wMlgxPzl2IN88US=>	MYLTRW5ITVJ?
SNU-423	NX;DV5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPVTWM2OD1yLkixOFIzKM7:TR?=	MWrTRW5ITVJ?
A704	M3:4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3hO2NKSzVyPUCuPFE4QThizszN	MVfTRW5ITVJ?
OVCAR-4	M4Oy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXkZpAyUUN3ME2wMlgyQTFzIN88US=>	MYPTRW5ITVJ?
NCI-H2347	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwOEK0NFEh\|ryP	Mom4V2FPT0WU
OCUB-M	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwOEK2O\|Uh\|ryP	NV7EXXIxW0GQR1XS
KYSE-450	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHs[W5xUUN3ME2wMlgzPzJ3IN88US=>	MVzTRW5ITVJ?
PFSK-1	NY[wb3NwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkmwTWM2OD1yLkizNFM6KM7:TR?=	MUXTRW5ITVJ?
A431	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4q1TmlEPTB;MD64N\|EyPiEQvF2=	MXXTRW5ITVJ?
MHH-ES-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HCeGlEPTB;MD64N\|Q2PyEQvF2=	MVjTRW5ITVJ?
HD-MY-Z	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrxbpFKSzVyPUCuPFQxQTJizszN	MnX2V2FPT0WU
RT-112	NUHpXVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHHe24{UUN3ME2wMlg1QTN5IN88US=>	NYH6W3Q5W0GQR1XS
KU-19-19	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nieGlEPTB;MD64OVEzOSEQvF2=	MoHtV2FPT0WU
HCC1569	Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfhTWM2OD1yLki1NlA4KM7:TR?=	MVvTRW5ITVJ?
RPMI-8866	NE\p[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\3V4lZUUN3ME2wMlg2QDJ{IN88US=>	NVXvXJVDW0GQR1XS
CAL-120	NXfEc3FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7DZYdyUUN3ME2wMlg3ODRzIN88US=>	NHfvU4dUSU6JRWK=
CAL-33	M3TkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTOeXk5UUN3ME2wMlg3PDl3IN88US=>	Mlu2V2FPT0WU
RKO	M1;IeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HTXWlEPTB;MD64OlgyPyEQvF2=	MXXTRW5ITVJ?
HCC1419	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETyNlVKSzVyPUCuPFY6OjhizszN	MWrTRW5ITVJ?
CP50-MEL-B	NVzw[I4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nkSGlEPTB;MD64PFM5PCEQvF2=	MYTTRW5ITVJ?
BPH-1	NFrnN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPEeZdQUUN3ME2wMlg5Ozl3IN88US=>	MWnTRW5ITVJ?
SF126	NYi1T5NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml71TWM2OD1yLki4O\|E1KM7:TR?=	NY\XTlVLW0GQR1XS
BHY	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjkTWM2OD1yLki4O\|M1KM7:TR?=	NFe1OYtUSU6JRWK=
BxPC-3	NG\4WG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDhTWM2OD1yLki4PFM{KM7:TR?=	NGDpN3ZUSU6JRWK=
ETK-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\kU5FKSzVyPUCuPFk{PzJizszN	M3PlUnNCVkeHUh?=
NCI-H1573	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTUTItNUUN3ME2wMlkxOjJ7IN88US=>	MlnBV2FPT0WU
C-33-A	M1jFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPPOFJKSzVyPUCuPVA1PDJizszN	NHjqc2RUSU6JRWK=
UACC-893	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGO2OYdKSzVyPUCuPVI5PTVizszN	MlThV2FPT0WU
RXF393	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f6fWlEPTB;MD65Nlg6PyEQvF2=	M{jvNnNCVkeHUh?=
MIA-PaCa-2	NHT2c2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LR[mlEPTB;MD65NlkzOiEQvF2=	M3fkXnNCVkeHUh?=
HCC1806	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWi0SnA3UUN3ME2wMlk{OjV4IN88US=>	MXPTRW5ITVJ?
DMS-114	NX3HOXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfwSXZDUUN3ME2wMlk{Pjd5IN88US=>	MlXSV2FPT0WU
MOLT-16	NWCweXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTBwOUO4OFUh\|ryP	NFS4RnBUSU6JRWK=
ACN	NGTyVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITySYRKSzVyPUCuPVQzPzdizszN	MXzTRW5ITVJ?
SNU-449	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXtTWM2OD1yLkm1PVI1KM7:TR?=	Mnz6V2FPT0WU
A427	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDQN\|RFUUN3ME2wMlk3OTl6IN88US=>	MYHTRW5ITVJ?
DEL	NFrt[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWftR48yUUN3ME2wMlk3Pzd\|IN88US=>	NYiySpNYW0GQR1XS
NCI-H1792	NY\JPJFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwOUexNFEh\|ryP	MnfPV2FPT0WU
A2058	MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XUNGlEPTB;MD65O\|M3KM7:TR?=	NHHtVZdUSU6JRWK=
SW13	M4fVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHjVYtKSzVyPUCuPVg{QTJizszN	MVnTRW5ITVJ?
T98G	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfoRZlKSzVyPUGuNFE{PjRizszN	MmPkV2FPT0WU
LU-134-A	MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ToS2lEPTB;MT6wNlY4PSEQvF2=	MkjEV2FPT0WU
GI-ME-N	MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jIemlEPTB;MT6wNlgzPyEQvF2=	MnX0V2FPT0WU
D-423MG	NV[4TZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkizTWM2OD1zLkCyPVY{KM7:TR?=	M4jQRXNCVkeHUh?=
PANC-03-27	NG\pPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTFwMEOxOFEh\|ryP	NIS1N4hUSU6JRWK=
P12-ICHIKAWA	NImyfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fFe2lEPTB;MT6wN\|QxPiEQvF2=	MWrTRW5ITVJ?
SCH	NYrNVnI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moj2TWM2OD1zLkCzOFUh\|ryP	MUHTRW5ITVJ?
D-566MG	MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLWboFKSzVyPUGuNFY4OjZizszN	NYexSZFKW0GQR1XS
OS-RC-2	NFvER4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTFwMEe5OEDPxE1?	M2PmS3NCVkeHUh?=
KOSC-2	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[zdmlEPTB;MT6wPFAzOSEQvF2=	M3\sTnNCVkeHUh?=
SH-4	MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;OTJNoUUN3ME2xMlA5PDNzIN88US=>	MkDyV2FPT0WU
786-0	NXX3TXBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFwMEi5N\|Qh\|ryP	NFXEfZNUSU6JRWK=
Mewo	M{myOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjTeWh{UUN3ME2xMlA6OjR6IN88US=>	MVfTRW5ITVJ?
AGS	MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfRdnNDUUN3ME2xMlA6PDV7IN88US=>	NIfnTplUSU6JRWK=
Daoy	M{LrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PCcGlEPTB;MT6wPVYzQCEQvF2=	NFjkc2JUSU6JRWK=
SW48	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUCxNGZ2UUN3ME2xMlExQTFzIN88US=>	MnvLV2FPT0WU
KYSE-180	M3LQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzRSJoyUUN3ME2xMlEyODJzIN88US=>	M17mRXNCVkeHUh?=
NH-12	M4fJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDkUYk{UUN3ME2xMlEyOjN5IN88US=>	MmO0V2FPT0WU
BE-13	M3\HNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTFwMUG3OVkh\|ryP	NV3U[3dEW0GQR1XS
ES3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTxV4RKSzVyPUGuNVMyPzFizszN	NEHLc5NUSU6JRWK=
NCI-H1092	M1\zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnCR3ViUUN3ME2xMlE{PCEQvF2=	MX7TRW5ITVJ?
NCI-H1755	M4WzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH1b3ByUUN3ME2xMlE{QTRzIN88US=>	NGC5ZodUSU6JRWK=
EKVX	NVP6[5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLrTWM2OD1zLkG0NFAyKM7:TR?=	NX[5dHI{W0GQR1XS
NB13	M1ruPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLIR4xKSzVyPUGuNVQ1PSEQvF2=	NUfxU3pxW0GQR1XS
NCI-H2405	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwMUS1O\|Qh\|ryP	NV\UTYFNW0GQR1XS
LS-411N	NEDpRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTFwMUWwNVch\|ryP	MkjIV2FPT0WU
MDA-MB-453	NX7SdnI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrCdlVKSzVyPUGuNVU3OjRizszN	M1nrPXNCVkeHUh?=
SCC-15	NXPOS4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PiU2lEPTB;MT6xOlk2PiEQvF2=	NGHKVIxUSU6JRWK=
C2BBe1	NHjYZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDISHlFUUN3ME2xMlE4ODV4IN88US=>	NX3HU41FW0GQR1XS
HT-144	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDQTWM2OD1zLkG3NFch\|ryP	M4m0enNCVkeHUh?=
HEC-1	M1HteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTFwMUe2Nlch\|ryP	MWfTRW5ITVJ?
HCE-T	NGr3OWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO1VpRKSzVyPUGuNVc6QDNizszN	NYX2Z2M{W0GQR1XS
IST-MEL1	NH;F[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnL3TWM2OD1zLkG5NFgzKM7:TR?=	MYHTRW5ITVJ?
Detroit562	NWSwelVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{G3e2lEPTB;MT6xPVQ{QSEQvF2=	Mn20V2FPT0WU
A4-Fuk	M{PrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLXTWM2OD1zLkKwOFQyKM7:TR?=	NFL2cnFUSU6JRWK=
HDLM-2	M4TMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\QfmlEPTB;MT6yNVMzPiEQvF2=	NXfVR2ZIW0GQR1XS
MKN7	M{LaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn:xTWM2OD1zLkKxO\|AzKM7:TR?=	M2TpWHNCVkeHUh?=
MDA-MB-415	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTFwMkG3NFIh\|ryP	NH2ydVVUSU6JRWK=
BT-20	M1fVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXleWtKSzVyPUGuNlI1PDRizszN	MkP3V2FPT0WU
NCI-H2030	NID5b2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zHOWlEPTB;MT6yOFExPiEQvF2=	M4nMUXNCVkeHUh?=
LS-123	NH[0dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzyTWM2OD1zLkK0O\|U{KM7:TR?=	NXT2N5RuW0GQR1XS
SK-MEL-3	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n2NWlEPTB;MT6yOFc4PiEQvF2=	M33nb3NCVkeHUh?=
KS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlS2TWM2OD1zLkK1NVcyKM7:TR?=	M1nY[XNCVkeHUh?=
LU-65	NXPLd29JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXRdohKSzVyPUGuNlU3ODZizszN	MUXTRW5ITVJ?
NCI-H596	NHrGcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjyXW1KSzVyPUGuNlU6OjlizszN	M2fqUnNCVkeHUh?=
KYSE-410	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHvT4dKSzVyPUGuNlcxOTRizszN	NF7lbWRUSU6JRWK=
NCI-H2228	NEnKRWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTFwMkexOlch\|ryP	Mo\CV2FPT0WU
LN-405	NU\QW5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwMkiwNlEh\|ryP	MojMV2FPT0WU
8505C	Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:zfI9KSzVyPUGuNlg5OjNizszN	MYnTRW5ITVJ?
BFTC-909	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLyTWM2OD1zLkK5OFM1KM7:TR?=	Mm\0V2FPT0WU
OC-314	NVrwOYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFwMkm5Nlkh\|ryP	MVXTRW5ITVJ?
NMC-G1	NYH1OFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DwVGlEPTB;MT6zNVE{PSEQvF2=	NFn0O5lUSU6JRWK=
SKG-IIIa	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXvV2RKSzVyPUGuN\|E1OjhizszN	MXzTRW5ITVJ?
GAK	M{PyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXxZ3NKSzVyPUGuN\|E5PThizszN	M12xfXNCVkeHUh?=
D-263MG	NWe2XIpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTFwM{K2OFEh\|ryP	MYLTRW5ITVJ?
NCI-H446	NHrQfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3TWVdKSzVyPUGuN\|I6ODJizszN	MVPTRW5ITVJ?
TGBC1TKB	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnCcIw5UUN3ME2xMlMzQTl6IN88US=>	MoXBV2FPT0WU
GCT	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe1SHd3UUN3ME2xMlM1OzR3IN88US=>	NWP5V\|NvW0GQR1XS
COR-L23	NVvQS21FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrxbJFrUUN3ME2xMlM1QDR3IN88US=>	NE\tcmFUSU6JRWK=
TK10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rIZmlEPTB;MT6zOVc6PyEQvF2=	NVyzPYhRW0GQR1XS
ES6	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rvTmlEPTB;MT6zOlM4PiEQvF2=	Mlf2V2FPT0WU
SW1088	NHXndIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HxOmlEPTB;MT6zOlYyOiEQvF2=	M1vNSHNCVkeHUh?=
AM-38	NHS4[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYS3eYtpUUN3ME2xMlM4OTl7IN88US=>	M2fyN3NCVkeHUh?=
CHP-134	M1\NUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPjXVhKSzVyPUGuN\|c5PDRizszN	M{m5TXNCVkeHUh?=
SW872	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjTbYJKSzVyPUGuN\|g2PTVizszN	NF3Qd5FUSU6JRWK=
LB831-BLC	NWfpPGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml24TWM2OD1zLkO5NFY4KM7:TR?=	NFvuRoFUSU6JRWK=
TE-12	NESxeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPaNWFKSzVyPUGuOFA3ODFizszN	MW\TRW5ITVJ?
LCLC-97TM1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTFwNEGwOFYh\|ryP	MVfTRW5ITVJ?
HCT-116	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfVTWM2OD1zLkSyPFU1KM7:TR?=	MVfTRW5ITVJ?
ALL-PO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXrUphKSzVyPUGuOFM4PzRizszN	M2TudnNCVkeHUh?=
EW-16	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUf3dItyUUN3ME2xMlQ{QDR{IN88US=>	NGnMN3pUSU6JRWK=
NCI-H661	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfYVYFKSzVyPUGuOFQ4PzVizszN	NEPoc4tUSU6JRWK=
TE-8	M1zRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFwNEW1OkDPxE1?	NWH2bHBUW0GQR1XS
TCCSUP	NH\IfXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTFwNE[5OkDPxE1?	NXz5OGREW0GQR1XS
SW1990	NUjrN3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFwNEe1N\|Mh\|ryP	Ml7kV2FPT0WU
UM-UC-3	NHPofVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\vTWM2OD1zLkS3Olc2KM7:TR?=	M13pe3NCVkeHUh?=
HuP-T4	NEHSfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3wZpZzUUN3ME2xMlQ5PjB5IN88US=>	MmDzV2FPT0WU
NCI-H1299	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHG4ZoZKSzVyPUGuOVAxQDZizszN	MULTRW5ITVJ?
RO82-W-1	NV\ORYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwNUKwPFEh\|ryP	M3TpXnNCVkeHUh?=
Becker	M1rGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTFwNUKxPFch\|ryP	M2jWbXNCVkeHUh?=
SNU-387	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrFbXhXUUN3ME2xMlUzOjRzIN88US=>	M3m1e3NCVkeHUh?=
CAL-85-1	NHzsZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ezRmlEPTB;MT61NlU6QSEQvF2=	MnPxV2FPT0WU
647-V	NF;aS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTFwNUO4PEDPxE1?	MX\TRW5ITVJ?
SBC-5	MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y1OWlEPTB;MT61OFU6OyEQvF2=	MnTNV2FPT0WU
NCI-H23	NVPNUFN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PNSGlEPTB;MT61OVcyPCEQvF2=	MX7TRW5ITVJ?
CGTH-W-1	MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFX3[VZKSzVyPUGuOVU5OTlizszN	NITEUXdUSU6JRWK=
SK-N-FI	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTFwNUW5NFgh\|ryP	M1z3TnNCVkeHUh?=
KM-H2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFwNU[0O\|Qh\|ryP	M1ziWHNCVkeHUh?=
KY821	NG\0S3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHhWGtoUUN3ME2xMlU3PjF5IN88US=>	MU\TRW5ITVJ?
RH-1	NXrnflB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3izXWlEPTB;MT61Olc3OiEQvF2=	M1Hnb3NCVkeHUh?=
KYSE-270	NYfOUWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTFwNUe0NlMh\|ryP	Mn\tV2FPT0WU
SF539	MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\4PHhKSzVyPUGuOVc6PjlizszN	MnLGV2FPT0WU
JEG-3	M4\YNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfkSGpHUUN3ME2xMlU5ODl2IN88US=>	NWPpbXpyW0GQR1XS
SCC-25	M3XuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknYTWM2OD1zLkW4OFMzKM7:TR?=	NIjlWIxUSU6JRWK=
SW1573	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1j4bGlEPTB;MT62NFE2QCEQvF2=	NYXXU4xsW0GQR1XS
EW-1	M37vfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDx[W46UUN3ME2xMlYyOzVzIN88US=>	NHfG[mRUSU6JRWK=
YKG-1	M3XreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTFwNkG0N\|gh\|ryP	NYqz[2FOW0GQR1XS
EW-11	NYDz[JpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlS5TWM2OD1zLk[xO\|QyKM7:TR?=	NUHp[4JYW0GQR1XS
DJM-1	MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnwTWM2OD1zLk[xPFI2KM7:TR?=	MWHTRW5ITVJ?
Calu-3	NWiycnBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3n6TWlEPTB;MT62OVIyOyEQvF2=	MVTTRW5ITVJ?
HT-3	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEX4cVZKSzVyPUGuOlU3PiEQvF2=	NF3FV2VUSU6JRWK=
NCI-H69	M2judGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfjVJRKSzVyPUGuOlc{PDNizszN	MnfnV2FPT0WU
NCI-H2126	NVW4bXR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2S3Z2lEPTB;MT62O\|c6PyEQvF2=	MmPwV2FPT0WU
RPMI-2650	M{jxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7CTWM2OD1zLk[4N\|E4KM7:TR?=	NFTHTm5USU6JRWK=
TE-6	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILpOllKSzVyPUGuO\|A5PzRizszN	MVPTRW5ITVJ?
MDA-MB-231	NIqyOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTFwN{G5PVMh\|ryP	NYjLc5lEW0GQR1XS
A2780	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XMeWlEPTB;MT63NlIxPyEQvF2=	MlHYV2FPT0WU
GOTO	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfFTWM2OD1zLkezOVYh\|ryP	NHTremtUSU6JRWK=
KYSE-70	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDEeIFKSzVyPUGuO\|Q1PDJizszN	M1vu[3NCVkeHUh?=
GMS-10	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv6TWM2OD1zLke0OlYzKM7:TR?=	M1;XVnNCVkeHUh?=
CaR-1	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHiUmg4UUN3ME2xMlc1QDF{IN88US=>	NXT6XppyW0GQR1XS
SW900	NGG3[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLhTWM2OD1zLke0PVk{KM7:TR?=	NGnk[XBUSU6JRWK=
BB49-HNC	NEXwbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPwTWM2OD1zLke1NVY5KM7:TR?=	NXXsOHJWW0GQR1XS
SNB75	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnUXG1xUUN3ME2xMlc2PDl{IN88US=>	MXrTRW5ITVJ?
SK-PN-DW	NFflVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorzTWM2OD1zLke1OlgzKM7:TR?=	M3fuPHNCVkeHUh?=
5637	NWPadJV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFwN{eyOlgh\|ryP	MljLV2FPT0WU
BT-474	NUP5cJFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYT2[FBIUUN3ME2xMlc5OTdzIN88US=>	NUfkPHpEW0GQR1XS
KM12	NX3TUGluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXVUFFiUUN3ME2xMlc6PzRzIN88US=>	NWP5VZUyW0GQR1XS
COLO-680N	M4nNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXhU4ZZUUN3ME2xMlgzOzhzIN88US=>	MVTTRW5ITVJ?
Saos-2	NFnDTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfLfmlKSzVyPUGuPFI1PDVizszN	NV7sPIxpW0GQR1XS
CAL-54	NVns[IFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLYTWM2OD1zLkizN\|E{KM7:TR?=	M2K1V3NCVkeHUh?=
U-118-MG	NXXlZ2plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnrO\|h7UUN3ME2xMlg1PjJ{IN88US=>	MkLVV2FPT0WU
TGBC24TKB	M4DmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TzbWlEPTB;MT64OVUxOSEQvF2=	MofUV2FPT0WU
NCI-H2052	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXMV2hKSzVyPUGuPFY1OSEQvF2=	MmTpV2FPT0WU
BB30-HNC	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHG3cY9KSzVyPUGuPFY1PjJizszN	MWfTRW5ITVJ?
KNS-81-FD	NYD4V4tkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;XTWM2OD1zLki5NVY2KM7:TR?=	MVLTRW5ITVJ?
HN	NXjzc4toT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwOEm1OFUh\|ryP	MmLNV2FPT0WU
ACHN	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTaTWM2OD1zLkmwO\|g3KM7:TR?=	MnzJV2FPT0WU
HSC-2	MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnVN\|k{UUN3ME2xMlkyODl4IN88US=>	M1zvPHNCVkeHUh?=
HCC2998	NFTGUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TZVWlEPTB;MT65N\|MzPSEQvF2=	MVfTRW5ITVJ?
HEL	M37HR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX4eow6UUN3ME2xMlk1OTh2IN88US=>	NHrPTGNUSU6JRWK=
SW684	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HTTWlEPTB;MT65O\|M4OSEQvF2=	M2q1OHNCVkeHUh?=
NCI-H1693	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTFwOUiwPFYh\|ryP	M4nQOXNCVkeHUh?=
8-MG-BA	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfh[3psUUN3ME2xMlk5OjFizszN	NHPzOXdUSU6JRWK=
OVCAR-8	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJwMECyPVUh\|ryP	M1vrUnNCVkeHUh?=
DSH1	NU\SfoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnrR3hKSzVyPUKuNFE4PzRizszN	MlnjV2FPT0WU
KYSE-520	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmOzTWM2OD1{LkCyNFQ6KM7:TR?=	NX3xbVNFW0GQR1XS
GB-1	M2C3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfEO\|RjUUN3ME2yMlAzPTd5IN88US=>	MYnTRW5ITVJ?
RCC10RGB	NF;aNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LlcGlEPTB;Mj6wOFg4OSEQvF2=	NXfLc5dLW0GQR1XS
SW954	M3;sV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\OcmRJUUN3ME2yMlA2ODN4IN88US=>	NEP2bIRUSU6JRWK=
IST-MES1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ixUmlEPTB;Mj6wOVU3QCEQvF2=	M1G0bHNCVkeHUh?=
AU565	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf2XVZKSzVyPUKuNFU6ODVizszN	MXPTRW5ITVJ?
CW-2	M1u4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTRTWM2OD1{LkC2PFc2KM7:TR?=	Mn2wV2FPT0WU
TE-1	M3Hubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfWTVVKSzVyPUKuNFk{PzdizszN	NVroVFljW0GQR1XS
KP-4	NWTzT5JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFu4bWlKSzVyPUKuNVA{OTJizszN	M3qyNHNCVkeHUh?=
SNU-C2B	M4nSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFGxSWVKSzVyPUKuNVA5OjNizszN	MnTKV2FPT0WU
NCI-H1395	NXfzPIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJwMUC5PFYh\|ryP	MV\TRW5ITVJ?
CAS-1	NITaVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHwTWM2OD1{LkGxOVQ3KM7:TR?=	M3\WcnNCVkeHUh?=
NCI-H1155	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2L6XmlEPTB;Mj6yNlY6KM7:TR?=	NVvPNWNIW0GQR1XS
SK-MEL-1	NELC[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4ixPWlEPTB;Mj6yPFE5OSEQvF2=	MonQV2FPT0WU
KINGS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml24TWM2OD1{LkOwNFg5KM7:TR?=	NFOzO2RUSU6JRWK=
ESS-1	NVnVVotKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTSUGdKSzVyPUKuN\|A2OSEQvF2=	M333ZnNCVkeHUh?=
PANC-10-05	NXnQZVV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTJwM{ewNlQh\|ryP	MkfrV2FPT0WU
HT-1376	NXrHZldQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTJwM{i3NFgh\|ryP	NEnZe2dUSU6JRWK=
LS-513	M4XZUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mon0TWM2OD1{LkO4PFc1KM7:TR?=	MX3TRW5ITVJ?
KNS-42	NUHFWZkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJwM{mxNFUh\|ryP	NH7U[olUSU6JRWK=
639-V	M2\zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwNEK3OVgh\|ryP	NUnLN2p6W0GQR1XS
SJRH30	NVTBVJVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXNTWM2OD1{LkS1NVYyKM7:TR?=	MUXTRW5ITVJ?
SW1783	M3rQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTJwNEewO\|gh\|ryP	Mnz5V2FPT0WU
NB6	NXv1[oVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTGWm9FUUN3ME2yMlQ5OjhizszN	MWXTRW5ITVJ?
SK-MEL-30	MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnp[JM6UUN3ME2yMlQ5QDNizszN	NF\EWm1USU6JRWK=
HCE-4	NHXCZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXqybXZvUUN3ME2yMlQ6PDB{IN88US=>	M4[2cHNCVkeHUh?=
NB10	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJwNEm0Nlkh\|ryP	M4HkUnNCVkeHUh?=
H-EMC-SS	NFXYOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPGTWM2OD1{LkW0OlUh\|ryP	MnrHV2FPT0WU
SK-HEP-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUL0eFhWUUN3ME2yMlU2OjN4IN88US=>	NGnmO45USU6JRWK=
HCC1395	NHXHZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DEd2lEPTB;Mj61OVY2PSEQvF2=	Ml3wV2FPT0WU
HuCCT1	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnwfVFKSzVyPUKuOVY{QSEQvF2=	M4nM[HNCVkeHUh?=
SiHa	MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF71Z2NKSzVyPUKuOVg4OTlizszN	MV\TRW5ITVJ?
EFO-21	NYXo[IhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnSSWY{UUN3ME2yMlU5PzZ2IN88US=>	NIricVdUSU6JRWK=
NCI-H1666	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fYbWlEPTB;Mj61PVA4PiEQvF2=	M3vafnNCVkeHUh?=
UMC-11	M1jHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLwZ\|hsUUN3ME2yMlU6QDZ6IN88US=>	NWrZe\|FpW0GQR1XS
COLO-679	M2mxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJwNkGyN\|Mh\|ryP	MVXTRW5ITVJ?
A388	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jsdWlEPTB;Mj62OVI2OyEQvF2=	MoT5V2FPT0WU
LB2518-MEL	NWKxblBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkeyTWM2OD1{Lk[1OFA5KM7:TR?=	NITuSGdUSU6JRWK=
EW-13	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfJZYZwUUN3ME2yMlY5PzZ6IN88US=>	NU\Qe\|U2W0GQR1XS
MLMA	M4XvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTJwNki4OVYh\|ryP	NYPvZoZ7W0GQR1XS
HOP-92	NVPseZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLOTWM2OD1{LkewNVEh\|ryP	NWDve5B5W0GQR1XS
NOMO-1	M2jOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPWVVhwUUN3ME2yMlcyPDR{IN88US=>	M3q1cnNCVkeHUh?=
NCI-H810	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkflTWM2OD1{LkeyNVk5KM7:TR?=	NVXZZXY6W0GQR1XS
769-P	M1[0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3j1R2lEPTB;Mj63NlI5KM7:TR?=	M4fhZnNCVkeHUh?=
SAS	NHHocFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nPfWlEPTB;Mj63OlUh\|ryP	NXfGV3dUW0GQR1XS
M059J	M1WydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXOTWM2OD1{Lke4N\|E5KM7:TR?=	MV7TRW5ITVJ?
RD	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7zRZFKSzVyPUKuO\|k1PzFizszN	MnHhV2FPT0WU
GT3TKB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrVTWM2OD1{LkizOFM{KM7:TR?=	M1LSSHNCVkeHUh?=
MZ7-mel	NH;zToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTsZ3VKSzVyPUKuPFY2ODJizszN	MYnTRW5ITVJ?
KYSE-510	NXTsXlV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX6TWM2OD1{Lki5OVA1KM7:TR?=	NFGz[29USU6JRWK=
NCI-N87	NVG5VI1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwOUG4NFch\|ryP	NVPtenFoW0GQR1XS
MKN1	NIC0VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTjOWZKSzVyPUOuNFAyPjNizszN	Ml72V2FPT0WU
NCI-H2170	NGPUdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTNwMEC0OVEh\|ryP	NUnMe4I4W0GQR1XS
OVCAR-3	NVLkbmNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PDW2lEPTB;Mz6wNlEyPSEQvF2=	MV7TRW5ITVJ?
KLE	NHPiVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTNwME[4NVIh\|ryP	MmKwV2FPT0WU
LB771-HNC	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnv[I5KSzVyPUOuNFk{PDNizszN	NUnMN3lPW0GQR1XS
MC116	M1HscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHUTWM2OD1\|LkGxNVEzKM7:TR?=	NWjUTphyW0GQR1XS
SCC-9	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkSwTWM2OD1\|LkGxN\|Y3KM7:TR?=	NV7F[2hCW0GQR1XS
U031	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTNwMUK0NlMh\|ryP	M1jN[XNCVkeHUh?=
LCLC-103H	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTNwMkO4PVQh\|ryP	MnLMV2FPT0WU
U-266	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLKTWM2OD1\|LkK3OlM{KM7:TR?=	MWXTRW5ITVJ?
JVM-2	M4nOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTNwM{KxOlQh\|ryP	NVfDXIpSW0GQR1XS
UACC-257	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPmTWM2OD1\|LkS2OFMyKM7:TR?=	M2jtPHNCVkeHUh?=
LB996-RCC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrSV5FxUUN3ME2zMlQ3PTB{IN88US=>	MojBV2FPT0WU
BT-549	NIi2NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfkNHdKSzVyPUOuOVAzODlizszN	M13JfHNCVkeHUh?=
NCI-H526	NYfh[4FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTqcFl1UUN3ME2zMlU1OTV6IN88US=>	M2myRnNCVkeHUh?=
RH-18	M2XZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPoRnlKSzVyPUOuOlE4QThizszN	NUXqZW9PW0GQR1XS
SW626	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe0Oo5XUUN3ME2zMlcyOTJ6IN88US=>	Mn3IV2FPT0WU
SK-N-AS	M1jXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmP0TWM2OD1\|LkezNlQ4KM7:TR?=	M4KyW3NCVkeHUh?=
IGR-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T1T2lEPTB;Mz63OFI1QCEQvF2=	Mm\XV2FPT0WU
NCI-H2291	M1fFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXwVIxKSzVyPUOuO\|U{OzZizszN	MULTRW5ITVJ?
NCI-H441	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofVTWM2OD1\|LkiyOFM{KM7:TR?=	MVLTRW5ITVJ?
D-247MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fK[GlEPTB;Mz64OlA{OSEQvF2=	M4LVdnNCVkeHUh?=
COLO-320-HSR	M3XER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1WwRWlEPTB;Mz65NVI4OSEQvF2=	MWrTRW5ITVJ?
A253	M2faeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LWRmlEPTB;Mz65NVQ{PiEQvF2=	M{ixe3NCVkeHUh?=
HT55	NW\pSZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTXTWM2OD1\|LkmxO\|c{KM7:TR?=	MUXTRW5ITVJ?
MZ1-PC	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTNwOUW4OlQh\|ryP	NVXuSlFSW0GQR1XS
RERF-LC-MS	M3Trfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlu4TWM2OD1\|Lkm2OVI2KM7:TR?=	M3T1VHNCVkeHUh?=
SF268	NXfHUmFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTRwMUK4PFEh\|ryP	M4XlfnNCVkeHUh?=
RMG-I	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LTTWlEPTB;ND6yNVQ2PCEQvF2=	NV3CeVVlW0GQR1XS
CFPAC-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHtXllZUUN3ME20MlIyPjh3IN88US=>	NYfkZlZkW0GQR1XS
S-117	Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37UNGlEPTB;ND6yNlAzPCEQvF2=	M2HhUHNCVkeHUh?=
NCI-H2122	NW\hT4wzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVToO\|V3UUN3ME20MlMxQTNzIN88US=>	MUPTRW5ITVJ?
J82	NF7odFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XEemlEPTB;ND6zN\|Q1OSEQvF2=	M4L0SnNCVkeHUh?=
CAL-72	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nGN2lEPTB;ND6zOVQ4PyEQvF2=	MX\TRW5ITVJ?
GP5d	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDqWIRpUUN3ME20MlQyOjl6IN88US=>	M{HpTnNCVkeHUh?=
UACC-62	M2GydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\LTWM2OD12LkS2OVQ2KM7:TR?=	M{fyTnNCVkeHUh?=
MS-1	NYLW[phiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTRwNEmxNVUh\|ryP	NWfYfIVsW0GQR1XS
RCM-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTRwNUK5NkDPxE1?	M1i4RnNCVkeHUh?=
IST-SL1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;k[2lEPTB;ND62OVM2QSEQvF2=	NUTOU2RFW0GQR1XS
SW756	NUHIXmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlOxTWM2OD12Lk[5NVM2KM7:TR?=	MYrTRW5ITVJ?
HCC38	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTRwN{GxPVch\|ryP	M{L3PXNCVkeHUh?=
YAPC	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NID1eJFKSzVyPUSuO\|E{OTNizszN	NVPUNlVOW0GQR1XS
DK-MG	NEnESJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPkRnZ{UUN3ME20Mlc5OTF{IN88US=>	MnXnV2FPT0WU
HCC1937	MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXKTWM2OD12Lki1NVI2KM7:TR?=	M3PB[nNCVkeHUh?=
OAW-28	NVX2UZpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmH1TWM2OD12LkmyOFM2KM7:TR?=	NYnwWW5DW0GQR1XS
MEG-01	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TQNWlEPTB;NT6wPFMzQCEQvF2=	Mn23V2FPT0WU
GI-1	NGOyOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\Eb5BKSzVyPUWuNlM1QDZizszN	NEfSbVZUSU6JRWK=
FADU	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTLTWM2OD13LkK3PFM4KM7:TR?=	NVL0No01W0GQR1XS
CAPAN-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTVwM{m0N\|Ih\|ryP	M{fVVXNCVkeHUh?=
TGBC11TKB	MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\4d5pKSzVyPUWuOFU4QDZizszN	MUfTRW5ITVJ?
DBTRG-05MG	NXXGW\|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDrOXdJUUN3ME21MlUxPTJizszN	M4r0Z3NCVkeHUh?=
ONS-76	M2nsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Lyc2lEPTB;NT61OVgxOSEQvF2=	NIrYe4xUSU6JRWK=
Ca-Ski	NF\U[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjFZYhKSzVyPUWuOlI2PjZizszN	NWDOe\|hTW0GQR1XS
COLO-741	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;PTWM2OD13LkexPVk2KM7:TR?=	M2nKVXNCVkeHUh?=
HT-29	NHTXTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DDfGlEPTB;NT64NFQ4PSEQvF2=	MYTTRW5ITVJ?
HCC1187	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTVwOEGwNFgh\|ryP	NGDEeI9USU6JRWK=
Capan-2	M3XDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXyZmJKSzVyPUWuPVU6QTRizszN	MmfTV2FPT0WU
NCI-H630	M2jJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTxenNKSzVyPU[uNVE1PDFizszN	MWDTRW5ITVJ?
COLO-678	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTZwMUWwPVIh\|ryP	NELUbGNUSU6JRWK=
D-502MG	NVjhTIZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDLTWM2OD14LkG3N\|M3KM7:TR?=	NGS4U49USU6JRWK=
NB17	NYjzPHZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvhVII6UUN3ME22MlI1QTR\|IN88US=>	M2PFXnNCVkeHUh?=
SK-MEL-24	NGO1S5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfZc\|ZKSzVyPU[uNlY1QSEQvF2=	MWfTRW5ITVJ?
NCI-SNU-5	NF65cY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Pn[GlEPTB;Nj6yO\|EyQCEQvF2=	NEO2NFZUSU6JRWK=
D-392MG	Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFz6c5dKSzVyPU[uN\|M{QTlizszN	MoXHV2FPT0WU
A498	NGPJW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHkN2lQUUN3ME22MlQxOzB{IN88US=>	NILOPGxUSU6JRWK=
OCI-AML2	NVTlUGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS1RXBvUUN3ME22MlQ2PDR3IN88US=>	MX7TRW5ITVJ?
HCC2157	MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLOTWM2OD14LkS1OlE3KM7:TR?=	MYTTRW5ITVJ?
C3A	Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHmyOpdKSzVyPU[uOVIxODRizszN	NFWxNZpUSU6JRWK=
NCI-H1650	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHC[WtJUUN3ME22MlcxPTJ{IN88US=>	MljJV2FPT0WU
DU-145	M1HYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHETWM2OD14Lke3NFMh\|ryP	MXfTRW5ITVJ?
COLO-829	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HoPGlEPTB;Nj63O\|g4OyEQvF2=	NWW1d3pJW0GQR1XS
LS-1034	M2LsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXaTWM2OD15LkC0OFEzKM7:TR?=	MnLZV2FPT0WU
HCC1954	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHGd4JbUUN3ME23MlQ5OTN2IN88US=>	NVnLeI0yW0GQR1XS
KURAMOCHI	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r6dGlEPTB;Nz60PFU{OyEQvF2=	NH[2bFhUSU6JRWK=
Mo-T	NIjqRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv6VGd6UUN3ME23MlUyPDl6IN88US=>	NIL4UWFUSU6JRWK=
OE19	NG\uNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mly4TWM2OD15Lk[1OVA{KM7:TR?=	NF\RbYtUSU6JRWK=
COR-L105	NGjZPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PlXGlEPTB;Nz63NVQzOSEQvF2=	NHfn[4xUSU6JRWK=
NCI-H2342	NEPMc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTdwN{G1NlEh\|ryP	NX;ne4NPW0GQR1XS
U-87-MG	NHP5c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLMR3NKSzVyPUiuNFM{OzRizszN	MULTRW5ITVJ?
MKN28	NUG3THJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDi[4xKSzVyPUiuNVE2OTVizszN	NFPCeXhUSU6JRWK=
HT-1197	M1GyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\yNXhKSzVyPUiuNlU6ODdizszN	MVnTRW5ITVJ?
ChaGo-K-1	NELvV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYf4bIszUUN3ME24MlM1OjR3IN88US=>	M3O2bXNCVkeHUh?=
NCI-H226	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXWzTmdJUUN3ME24MlQ1OzNzIN88US=>	M3f6SXNCVkeHUh?=
NCI-H2029	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPBdWJUUUN3ME25MlA3PzV7IN88US=>	MXfTRW5ITVJ?
TE-11	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTNTWM2OD17LkS1OVg5KM7:TR?=	M3HTRXNCVkeHUh?=
ZR-75-30	NW\yWVRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DKV2lEPTB;OT65NlY{PCEQvF2=	NIjibYlUSU6JRWK=
SW837	M1rCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[yV2lEPTB;MUCuNlI6OyEQvF2=	M4OzW3NCVkeHUh?=
NCI-H1651	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPqOGNsUUN3ME2xNE4zOzJ4IN88US=>	NHLCNGtUSU6JRWK=
NCI-H727	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLGNI9uUUN3ME2xNE41PDl3IN88US=>	M2LZPHNCVkeHUh?=
NCI-H358	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;MXmlEPTB;MUCuPFM3PSEQvF2=	NH72[4FUSU6JRWK=
NCI-H2087	NIL3XY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUniPXZ1UUN3ME2xNU4xPDN2IN88US=>	NY\KbYFUW0GQR1XS
FTC-133	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfQcog6UUN3ME2xNU41ODVzIN88US=>	NWjzeWQ1W0GQR1XS
LAN-6	M2PpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4S1[2lEPTB;MUKuNVI1KM7:TR?=	NGLrRndUSU6JRWK=
NCI-H1838	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjUeppDUUN3ME2xNk42OTVzIN88US=>	Mo[5V2FPT0WU
Calu-6	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTEdphzUUN3ME2xOE4yODJzIN88US=>	NGXCblJUSU6JRWK=
HCC70	NH3DSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTF2LkS1NUDPxE1?	MUjTRW5ITVJ?
KARPAS-299	M2jp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfnZ2FKSzVyPUG1MlIyPTlizszN	NXThWmZQW0GQR1XS
CAL-27	NX;Le5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTOVot7UUN3ME2xOU4{QDR\|IN88US=>	MmDBV2FPT0WU
NCI-H82	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrvfplKSzVyPUG1MlU{OiEQvF2=	NVn4c3FRW0GQR1XS
no-10	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33xTGlEPTB;MUWuPVM5KM7:TR?=	Mn;OV2FPT0WU
U251	MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2noTmlEPTB;MU[uN\|Y4PSEQvF2=	M{nifnNCVkeHUh?=
TE-9	MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLUUHZyUUN3ME2xO{42OTZ4IN88US=>	MlrwV2FPT0WU
TE-10	NG\OcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTF7LkC2NFch\|ryP	MWnTRW5ITVJ?
COLO-824	M13Y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLlVYV[UUN3ME2yNE46Ojd4IN88US=>	M4XQZ3NCVkeHUh?=
HuP-T3	NWH0RVRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2f1W2lEPTB;MkGuNFc1QCEQvF2=	M1nwdXNCVkeHUh?=
KALS-1	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDtTVc1UUN3ME2yNU4yPzVizszN	MnjRV2FPT0WU
L-428	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\hR2lEPTB;MkGuOFAyPiEQvF2=	M2fEeXNCVkeHUh?=
JAR	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonXTWM2OD1{MT61NFIh\|ryP	MoDpV2FPT0WU
DoTc2-4510	NGG2WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfJcZhKSzVyPUKzMlg1PzVizszN	MV7TRW5ITVJ?
ABC-1	M2e3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJ4Lke5OVch\|ryP	NXHWTm92W0GQR1XS
MHH-NB-11	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\oNGlEPTB;M{OuN\|Q3PCEQvF2=	NY\neFJDW0GQR1XS
SW1463	M1\6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XQdmlEPTB;M{OuPVg{KM7:TR?=	M4npOHNCVkeHUh?=
SW1417	NVjHSmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq3TWM2OD1\|Nz6wPVUzKM7:TR?=	Ml;WV2FPT0WU
NB12	NITRdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\TWHlKSzVyPUO5MlQ3PTVizszN	NXu5UIw1W0GQR1XS
NY	NFr6N\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\jTWM2OD12MT6zNlAyKM7:TR?=	MWrTRW5ITVJ?
H1048	M3HiUWFxd3C2b4Ppd{BCe3OjeR?=	MVi1NFAhdk1?	MkfTO\|IhcA>?		MVPubIFv[2W\|IFHCWE0zPjQkgKPpcoR2[2WmIHHwc5B1d3Orcx?=	NUjXemdwOjV5M{e1OFI>
H86	MYDBdI9xfG:\|aYOgRZN{[Xl?	NEnOVHo2ODBibl2=	MUS3NkBp		NHnXRnhvcGGwY3XzJGFDXC1{NkRihLNqdmS3Y3XkJIFxd3C2b4Ppdy=>	MlnkNlU4Ozd3NEK=
H196	M2jXeGFxd3C2b4Ppd{BCe3OjeR?=	NFHrTGo2ODBibl2=	NXH4cXJjPzJiaB?=		MoLWcohidmOnczDBRnQuOjZ\|4pETbY5lfWOnZDDhdI9xfG:\|aYO=	NXjRcIJPOjV5M{e1OFI>
H446	NVe4WnlSSXCxcITvd4l{KEG\|c3H5	NU\FTXJrPTByIH7N	NVPG[2RFPzJiaB?=		NW\1VHZodmijbnPld{BCSlRvMk[z5qCUcW6mdXPl[EBieG:ydH;zbZM>	NV3iV48zOjV5M{e1OFI>
TFK-1	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEjtWJQ4OiCq	MoHmSG1UVw>?	M{jRXGlEPTB;NEegcm0>	MlO3NlUyPTJ{NES=
EGI-1	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvqbJdWPzJiaB?=	NFjyZ2pFVVOR	NGTwdJpKSzVyPUWzJI5O	NWq5NYVSOjVzNUKyOFQ>
OCI/AML3	NF2ySo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfDNo4xNjJizszN	MnK4OFghcA>?		NX;ydI93\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JJNmdHWvZYTpcolj	MYiyOFc{QTN7Mx?=
U937	NHr6eoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqwd5QxNjJizszN	MoGxOFghcA>?		MUTlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	NFH0cmwzPDd\|OUO5Ny=>
MOLM13	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjaNE4zKM7:TR?=	NEf4TXY1QCCq		MVrlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGmwZIXj[YQh[nlic3XseY1mfGmwaXK=	M33xbVI1PzN7M{mz
MCF7	M2\FUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[ydnREOjBibl2=	NFfIfIg4OiCq	NV\uW2ZuTkKV	MYPy[YR2[2W\|IITo[UBRTUySMT3t[YRq[XSnZDDpcoNz\WG\|ZTDpckBk\WyuII\pZYJqdGm2eR?=	NHLITYczPDZ6OEC0Oi=>
TamR	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7qSIpKSzVyPUG45qCKdk1?	MVyyOFQ2PzB4OR?=
MCF7-X	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fvVGlEPTB;MkSgcm0>	NWDMboZ1OjR2NUewOlk>
T47D-tamR	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PHOmlEPTB;MUmgcm0>	M1[x[lI1PDV5ME[5
293T	NWL0eJo1TnWwY4Tpc44hSXO\|YYm=	MkS0NlAhdk1?	M3XYXVMhcA>?		NHHaO5BlcXO{dYD0d{BCc3RvbXXkbYF1\WRiVFnGMWlCKHO2YXLpcIl1gSxidILhcpNtd2OjdHnvckwh[W6mIHHjeIl3cXS7	NXjjWmpNOjR\|NkO0OFk>
SW620	M1LRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSwMlAxOS1zMN88US=>	NGXmSm4zPCCq		M{ixVolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYOgeIhmKGOxbnPlcpRz[XSrb36gdol{\XN?	MoH0NlQ{PjN2NEm=
Huh7	NX7Ob21lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7YOU0yODBibl2=	M2nWPVAuOjRiaB?=	NYLFToM2TE2VTx?=	NEH5R5NqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	M{XCUFI1Ojl5M{Cw
Hep3B	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHoc5E2NTFyMDDuUS=>	M1TLW\|AuOjRiaB?=	NGTOSo9FVVOR	MonUbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NXHHS5dLOjR{OUezNFA>
Huh7	NVXyTZlRTnWwY4Tpc44hSXO\|YYm=	MYqxNFAhdk1?	MojGNVIhcA>?	NWrW[mtUTE2VTx?=	NVnRSWRxcW6mdXPld{BifXSxcHjh[5nDqA>?	MUKyOFI6PzNyMB?=
U87-MG	NVHKO2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rlPFczKGh?		Mn3pS2k2OOLCiU5ihKk4QSCwTdMg	NYrRT2VPOjR{NEm2OFA>
L3.6pl	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHwNUDPxE1?	NFXrdWQ4OiCq		MWnpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBDVVNvN{e3OlA4	MYiyOFI{OzN7OR?=
TE671	NUnYVGlUSXCxcITvd4l{KEG\|c3H5	NUD6cm12OSEQvF2=	MnLFOFghcA>?		MVXpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDBRnQuPzN5	M{Xse\|I1OTN\|MkG4
RD	NIjjcYpCeG:ydH;zbZMhSXO\|YYm=	NHK2b\|YyKM7:TR?=	MkizOFghcA>?		M1HSWolv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGFDXC15M{e=	NH7ScIUzPDF\|M{KxPC=>
RMS13	NXnoUIhPSXCxcITvd4l{KEG\|c3H5	NGPUcGwyKM7:TR?=	NYnjXplyPDhiaB?=		NITTTm9qdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	Mn;LNlQyOzN{MUi=
RH30	M1:zbWFxd3C2b4Ppd{BCe3OjeR?=	NELIS2EyKM7:TR?=	MkjhOFghcA>?		NIDIfZpqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBCSlRvN{O3	M4Oze\|I1OTN\|MkG4
Hep-2	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTDfYcxNjBzLUGg{txO	MkjZNVIuQTZiaB?=		MmXGbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NEW3flUzPDFyM{e0PS=>
SCC-9	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDvZmwxNjBzLUGg{txO	NUXFSFd3OTJvOU[gbC=>		M1y3[Ilv[3KnYYPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MYeyOFExOzd2OR?=
Hep-2	NVzaUY9WTnWwY4Tpc44hSXO\|YYm=	NG[xTW8xNjFxMD61JO69VQ>?	NYHYUVRSOjRiaB?=		M13VNYJtd2OtczDtWG9TSzFiYX7kJI1VV1KFMjDhZ5RqfmG2aX;u	MUGyOFExOzd2OR?=
SCC-9	MoLQSpVv[3Srb36gRZN{[Xl?	NIXQb5ExNjFxMD61JO69VQ>?	MVOyOEBp		NIjxdWRjdG:la4OgcXRQWkNzIHHu[EBuXE:UQ{KgZYN1cX[jdHnvci=>	NW\0fpE{OjRzMEO3OFk>
PANC-1	MlHVRZBweHSxc3nzJGF{e2G7	M4nhZlUxOCCwTR?=	MX20PEBp		M{X0W5NmdnOrdHn6[ZMheGGwY4LlZZRq[yClYX7j[ZIh[2WubIOgeI8hemGmaX;0bIVz[XC7	NWL6c5F2OjN6OE[yPVQ>
RMG2	NV\VVXoxSXCxcITvd4l{KEG\|c3H5	MVyxMVExODBibl2=	Mn3yO\|IhcA>?	NUXGSmNPTkKV	M4\C[4lvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	MnvVNlM3OTV4M{G=
HAC2	NW\ZUHVKSXCxcITvd4l{KEG\|c3H5	MXexMVExODBibl2=	NVLDWI1mPzJiaB?=	NUnyc205TkKV	M2L2UolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5	Mk[xNlM3OTV4M{G=
HT-29	MVzBdI9xfG:\|aYOgRZN{[Xl?	Ml7NNUDPxE1?	MVi3NkBp		NGDFS5ZifHSnboXheIV{KDVvRmWtbY5lfWOnZDDj[YxtKGSnYYTo	M3Syd\|IyQTR7MUKx
DLD1	M1LmR2Fxd3C2b4Ppd{BCe3OjeR?=	NXHqd2xOOSEQvF2=	M2HlO\|czKGh?		Ml\2ZZR1\W63YYTld{A2NU[XLXnu[JVk\WRiY3XscEBl\WG2aB?=	NHnicogzOTl2OUGyNS=>
HT-29	MYXGeY5kfGmxbjDBd5NigQ>?	NGDZPJkyKM7:TR?=	NWH1TmQ{PzJiaB?=		MVjpcoR2[2W\|IHH1eI9xcGGpeTD0c{Bkd26oZYKgZ5l1d3C{b4TlZ5Rqd25?	M1GybVIyQTR7MUKx
DLD1	NITRWFZHfW6ldHnvckBCe3OjeR?=	NWPTVId7OSEQvF2=	Mlu1O\|IhcA>?		MkXPbY5lfWOnczDheZRweGijZ4mgeI8h[2:wZnXyJIN6fG:ycn;0[YN1cW:w	NVLEboNFOjF7NEmxNlE>
Rh41	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorlTWM2OD1\|MD63JI5O	NEDUW24zOTN\|N{[3PS=>
Rh18	NUDjUItVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO0TWM2OD12MT60JI5O	NXLsOGV6OjF\|M{e2O\|k>
Rh30	Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHXTWM2OD1zNDDuUS=>	M2nLVVIyOzN5Nke5
BT-12	M3yzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DqOWlEPTB;MkSuO{BvVQ>?	MmXwNlE{Ozd4N{m=
CHLA-266	MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PubWlEPTB;MT6xJI5O	MkPVNlE{Ozd4N{m=
TC-71	NYDENVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33YeWlEPTB;NE[uOUBvVQ>?	M{nESVIyOzN5Nke5
CHLA-9	NXjMSo05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\KTWM2OD1zNT6zJI5O	MoDuNlE{Ozd4N{m=
CHLA-10	MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3xSXBWUUN3ME2zMlkhdk1?	MWeyNVM{PzZ5OR?=
CHLA-258	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHNbGdFUUN3ME2xNE41KG6P	M1GwbVIyOzN5Nke5
GBM2	NV31[25TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j1e2lEPTB;NECuO{BvVQ>?	MV:yNVM{PzZ5OR?=
NB-1643	M4LCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jNU2lEPTB;M{OuPEBvVQ>?	NVe0WHd{OjF\|M{e2O\|k>
NB-EBc1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fGNWlEPTB;MkeuNUBvVQ>?	MVyyNVM{PzZ5OR?=
CHLA-90	M2iyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\MR2lEPTB;M{SuOUBvVQ>?	MVKyNVM{PzZ5OR?=
CHLA-136	NX;ZUohNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojPTWM2OD1zNkKuOkBvVQ>?	M37sOFIyOzN5Nke5
NALM-6	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TLNGlEPTB;M{KuPUBvVQ>?	NWLmdm51OjF\|M{e2O\|k>
COG-LL-317	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfw[YFKSzVyPUGuN{BvVQ>?	MUOyNVM{PzZ5OR?=
RS4;11	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TNeWlEPTB;M{Wgcm0>	M1z5[VIyOzN5Nke5
MOLT-4	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrSZo9KSzVyPUiuOkBvVQ>?	MortNlE{Ozd4N{m=
CCRF-CEM	M4rT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrzRlkyUUN3ME20MlEhdk1?	M2DWWVIyOzN5Nke5
Kasumi-1	MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmCyTWM2OD1zLkSgcm0>	NGHWSlQzOTN\|N{[3PS=>
Karpas-299	NY\Od\|F2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX2xXXY6UUN3ME2yNU44KG6P	NHzVZ4czOTN\|N{[3PS=>
Ramos-RA1	NF;sXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13RPGlEPTB;OD6yJI5O	NIj2NVEzOTN\|N{[3PS=>
H838	MnvzSpVv[3Srb36gRZN{[Xl?	NH[4R2IyKM7:TR?=	M1OzPVQ5KGh?		M3zjXolv\HWlZYOgZ4VtdCCjdYTvdIhi\3l?	MV[yNFM3PDFzMx?=
H838	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrDWlExNTNizszN	M3vY[\|czKGh?		Ml\GbY5lfWOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh[XW2b4DoZYd6	NIflS3YzODB{OEi1OC=>
A549	NUnYN45uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3FNE0{KM7:TR?=	NEjiblg4OiCq		NVLCSmxGcW6mdXPld{Boem:5dHigbY5pcWKrdHnvckBidmRiYYX0c5Bp[We7	MUWyNFAzQDh3NB?=

... Click to View More Cell Line Experimental Data

In vivo

AZD8055 inhibits the pS6 and pAkt in U87MG and A549 xenografts at 2.5/10 mg/kg, which leads to tumor growth inhibition. AZD8055 shows significant antitumor activity in many xenografts, including U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA at a dose of 10/20 mg/kg. ^[1] AZD8055 induces ~40% reduction in tumour volume, accompanied by ablation of phosphorylation of Akt, S6K and SGK protein kinases. Administration of AZD8055 (5mg/kg, Bid) and SAHA (100 mg/kg/d) results in complete tumor growth inhibition in PTEN+/−LKB1+/hypo xenografts without side effects on mice by inhibition of mTORC1 and mTORC2 signaling. ^[4]

Protocol

Kinase Assay:^[1]	+ Expand Cell-based determinations of mTOR inhibition: A high-throughput screening cell-based assay is developed using MDA-MB-468 cells to detect mTORC1 and mTORC2 activity. Cells are exposed for 2 hours to increasing concentrations of AZD8055. At the end of the incubation period, cells are fixed, washed, and probed with antibodies against S473 pAkt or against S235/236 phosphorylated S6 (pS6). Levels of phosphorylation are assessed using an Acumen laser scanning cytometer.
Cell Research:^[1]	+ Expand Cell lines: U87MG, A549 and H838 cells Concentrations: 1 nM - 1 μM Incubation Time: 72 to 96 hours Method: Cells are exposed to AZD8055 for 72 to 96 hours and stained for cell nuclei (0.03 mg/mL Hoechst 33342) and acidic vesicles (1 μg/mL acridine orange). Images are captured at 450 and 536 nm on an ArrayScan II platform, and the percentage of acidic vesicles and the number of cells are quantified. For LC3 assessment, cells are exposed to e64d/pepstatin (10 μg/mL) for 30 to 90 min before incubation with AZD8055. Cells are lysed on ice and analyzed by immunoblotting. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: U87MG, BT474c, A549, Calu-3, LoVo, SW620, PC3 and MES-SA U87-MG and A549 are established in pathogen-free, female nude mice (nu/nu:Alpk). Formulation: Dissolved in captisol (CyDex, pH 3.0) and diluted to a final captisol concentration of 30% (w/v) Dosages: 2.5-20 mg/kg Administration: Oral gavage once or twice daily (Only for Reference)

References

[4] García-Martínez JM, et al. Br J Cancer, 2011, 104(7), 1116-1

+ Expand

Solubility (25°C)

In vitro	DMSO	50 mg/mL warmed (107.4 mM)
	Ethanol	3 mg/mL (6.44 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD8055 SDF

Molecular Weight	465.54
Formula	C₂₅H₃₁N₅O₄
CAS No.	1009298-09-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT01316809	Completed	Glioblastoma Multiforme\|Anaplastic Astrocytoma\|Anaplastic Oligodendroglioma\|Malignant Glioma\|Brainstem Glioma	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	March 4 2011	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00999882	Completed	Cancer\|Advanced Hepatocellular Carcinoma	AstraZeneca	October 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1
NCT00973076	Completed	Cancer\|Solid Tumors\|Advanced Solid Malignancies	AstraZeneca	August 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products4

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
Torin 1

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128,TAK-228)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 40 Publications

8 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

AZD8055

Cited by 40 Publications

8 Customer Reviews

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD8055 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)